Literature DB >> 25625001

Role of radiotherapy in the management of hepatocellular carcinoma: A systematic review.

Maria-Aggeliki Kalogeridi1, Anna Zygogianni1, George Kyrgias1, John Kouvaris1, Sofia Chatziioannou1, Nikolaos Kelekis1, Vassilis Kouloulias1.   

Abstract

Many patients with hepatocellular carcinoma (HCC) present with advanced disease, not amenable to curative therapies such as surgery, transplantation or radiofrequency ablation. Treatment options for this group of patients include transarterial chemoembolization (TACE) and radiation therapy. Especially TACE, delivering a highly concentrated dose of chemotherapy to tumor cells while minimizing systemic toxicity of chemotherapy, has given favorable results on local control and survival. Radiotherapy, as a therapeutic modality of internal radiation therapy with radioisotopes, has also achieved efficacious tumor control in advanced disease. On the contrary, the role of external beam radiotherapy for HCC has been limited in the past, due to the low tolerance of surrounding normal liver parenchyma. However, technological innovations in the field of radiotherapy treatment planning and delivery, have provided the means of delivering radical doses to the tumor, while sparing normal tissues. Advanced and highly conformal radiotherapy approaches such as stereotactic body radiotherapy and proton therapy, evaluated for efficacy and safety for HCC, report encouraging results. In this review, we present the role of radiotherapy in hepatocellular carcinoma patients not suitable for radical treatment.

Entities:  

Keywords:  Hepatocellular carcinoma; Hyperthermia; Radio-embolization; Radiotherapy; Review

Year:  2015        PMID: 25625001      PMCID: PMC4295187          DOI: 10.4254/wjh.v7.i1.101

Source DB:  PubMed          Journal:  World J Hepatol


  126 in total

Review 1.  Partial volume tolerance of the liver to radiation.

Authors:  Laura A Dawson; Randall K Ten Haken
Journal:  Semin Radiat Oncol       Date:  2005-10       Impact factor: 5.934

2.  Clinical results and risk factors of proton and carbon ion therapy for hepatocellular carcinoma.

Authors:  Shohei Komatsu; Takumi Fukumoto; Yusuke Demizu; Daisuke Miyawaki; Kazuki Terashima; Ryohei Sasaki; Yuichi Hori; Yoshio Hishikawa; Yonson Ku; Masao Murakami
Journal:  Cancer       Date:  2011-04-14       Impact factor: 6.860

3.  Stereotactic body radiation therapy in recurrent hepatocellular carcinoma.

Authors:  Wen-Yen Huang; Yee-Min Jen; Meei-Shyuan Lee; Li-Ping Chang; Chang-Ming Chen; Kai-Hsiung Ko; Kuen-Tze Lin; Jang-Chun Lin; Hsing-Lung Chao; Chun-Shu Lin; Yu-Fu Su; Chao-Yueh Fan; Yao-Wen Chang
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-02-17       Impact factor: 7.038

4.  Stereotactic radiotherapy of hepatocellular carcinoma: preliminary results.

Authors:  C Louis; S Dewas; X Mirabel; T Lacornerie; A Adenis; F Bonodeau; E Lartigau
Journal:  Technol Cancer Res Treat       Date:  2010-10

5.  Long-term results of hepatic artery fluorodeoxyuridine and conformal radiation therapy for primary hepatobiliary cancers.

Authors:  J M Robertson; T S Lawrence; J C Andrews; S Walker; M L Kessler; W D Ensminger
Journal:  Int J Radiat Oncol Biol Phys       Date:  1997-01-15       Impact factor: 7.038

6.  Long-term clinical outcome of phase IIb clinical trial of percutaneous injection with holmium-166/chitosan complex (Milican) for the treatment of small hepatocellular carcinoma.

Authors:  Ja Kyung Kim; Kwang-Hyub Han; Jong Tae Lee; Yong Han Paik; Sang Hoon Ahn; Jong Doo Lee; Kwan Sik Lee; Chae Yoon Chon; Young Myoung Moon
Journal:  Clin Cancer Res       Date:  2006-01-15       Impact factor: 12.531

7.  Local radiotherapy for patients with unresectable hepatocellular carcinoma.

Authors:  Won Park; Do Hoon Lim; Seung Woon Paik; Kwang Cheol Koh; Moon Seok Choi; Cheol Keun Park; Byung Chul Yoo; Jeong Eun Lee; Min Kyu Kang; Young Je Park; Hee Rim Nam; Yong Chan Ahn; Seung Jae Huh
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-03-15       Impact factor: 7.038

8.  Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis.

Authors:  Laura M Kulik; Brian I Carr; Mary F Mulcahy; Robert J Lewandowski; Bassel Atassi; Robert K Ryu; Kent T Sato; Al Benson; Albert A Nemcek; Vanessa L Gates; Michael Abecassis; Reed A Omary; Riad Salem
Journal:  Hepatology       Date:  2008-01       Impact factor: 17.425

9.  Toxicity of azathioprine and monocrotaline in murine sinusoidal endothelial cells and hepatocytes: the role of glutathione and relevance to hepatic venoocclusive disease.

Authors:  L D DeLeve; X Wang; J F Kuhlenkamp; N Kaplowitz
Journal:  Hepatology       Date:  1996-03       Impact factor: 17.425

Review 10.  Liver transplantation for hepatocellular carcinoma.

Authors:  Vincenzo Mazzaferro; Yun Shin Chun; Ronnie T P Poon; Myron E Schwartz; Francis Y Yao; J Wallis Marsh; Sherrie Bhoori; Sung-Gyu Lee
Journal:  Ann Surg Oncol       Date:  2008-01-31       Impact factor: 5.344

View more
  42 in total

1.  Consensus for Radiotherapy in Hepatocellular Carcinoma from The 5th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2014): Current Practice and Future Clinical Trials.

Authors:  Hee Chul Park; Jeong Il Yu; Jason Chia-Hsien Cheng; Zhao Chong Zeng; Ji Hong Hong; Michael Lian Chek Wang; Mi Sook Kim; Kwan Hwa Chi; Po-Ching Liang; Rheun-Chuan Lee; Wan-Yee Lau; Kwang Hyub Han; Pierce Kah-Hoe Chow; Jinsil Seong
Journal:  Liver Cancer       Date:  2016-05-03       Impact factor: 11.740

Review 2.  Proton therapy for hepatocellular carcinoma: Current knowledges and future perspectives.

Authors:  Gyu Sang Yoo; Jeong Il Yu; Hee Chul Park
Journal:  World J Gastroenterol       Date:  2018-07-28       Impact factor: 5.742

Review 3.  Radiotherapy as valid modality for hepatocellular carcinoma with portal vein tumor thrombosis.

Authors:  Jeong Il Yu; Hee Chul Park
Journal:  World J Gastroenterol       Date:  2016-08-14       Impact factor: 5.742

4.  Diffusion-weighted MRI and 18F-FDG PET correlation with immunity in early radiotherapy response in BNL hepatocellular carcinoma mouse model: timeline validation.

Authors:  Yi-Hsiu Chung; Ching-Fang Yu; Shao-Chieh Chiu; Han Chiu; Shin-Ting Hsu; Ching-Rong Wu; Chung-Lin Yang; Ji-Hong Hong; Tzu-Chen Yen; Fang-Hsin Chen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-05-24       Impact factor: 9.236

5.  A novel oncolytic adenovirus inhibits hepatocellular carcinoma growth.

Authors:  Yu-Huan Bai; Xiao-Jing Yun; Yan Xue; Ting Zhou; Xin Sun; Yan-Jing Gao
Journal:  J Zhejiang Univ Sci B       Date:  2019 Dec.       Impact factor: 3.066

Review 6.  Interventional Oncology Approach to Hepatic Metastases.

Authors:  Cathal O'Leary; Michael C Soulen; Susan Shamimi-Noori
Journal:  Semin Intervent Radiol       Date:  2020-12-11       Impact factor: 1.513

Review 7.  Management of liver cancer. The Surgeon's point of view.

Authors:  Pierre Rabinel; Damien Dousse; Fabrice Muscari; Bertrand Suc
Journal:  Rep Pract Oncol Radiother       Date:  2017-03-23

Review 8.  Pathology and images of radiation-induced hepatitis: a review article.

Authors:  Shigeyuki Takamatsu; Kazuto Kozaka; Satoshi Kobayashi; Norihide Yoneda; Kotaro Yoshida; Dai Inoue; Azusa Kitao; Takahiro Ogi; Tetsuya Minami; Wataru Kouda; Tomoyasu Kumano; Nobukazu Fuwa; Osamu Matsui; Toshifumi Gabata
Journal:  Jpn J Radiol       Date:  2018-03-05       Impact factor: 2.374

Review 9.  Curative-Intent Therapies in Localized Hepatocellular Carcinoma.

Authors:  Cathal O'Leary; Mary Mahler; Michael C Soulen
Journal:  Curr Treat Options Oncol       Date:  2020-03-19

10.  Therapeutic usability of two different fiducial gold markers for robotic stereotactic radiosurgery of liver malignancies: A pilot study.

Authors:  Maria Marsico; Tommaso Gabbani; Lorenzo Livi; Maria Rosa Biagini; Andrea Galli
Journal:  World J Hepatol       Date:  2016-06-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.